Product How it works Pricing Blog FAQ About Contact
Neurogene

Neurogene (NASDAQ: NGNE) revenue

Neurogene reported revenue of $0.0m for fiscal 2025, 100.0% less than in fiscal 2024 ($0.9m).

Neurogene's best year of the last 4 was fiscal 2018.

Revenue, in millions of US dollars25.020180.020230.920240.02025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$0.0m−100.0%−$103.3m—
2024$0.9m—−$82.6m−8,930.3%
2023$0.0m—−$55.6m—
2018$25.0m—−$32.6m−130.5%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Neurogene revenue compared with its sector

By revenue for its latest fiscal year, Neurogene ranks 411th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Neurogene, −100.0%.

RankCompanyRevenueRevenue growth
409thFulcrum Therapeutics$0.0m−100.0%
410thMonopar Therapeutics$0.0m—
411thNeurogene$0.0m−100.0%
412thNkarta$0.0m—
413thPalisade Bio$0.0m—

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Neurogene

How much revenue did Neurogene make in fiscal 2025?
Neurogene reported revenue of $0.0m for fiscal 2025, compared with $0.9m in fiscal 2024.
What was the best year for revenue at Neurogene?
Of its last 4 fiscal years, fiscal 2018, with $25.0m.
Where does Neurogene rank in its sector by revenue?
It ranks 411th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Neurogene come from?
From the annual report (Form 10-K) that Neurogene files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Neurogene files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2018. More on Neurogene: the Neurogene page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.